01:42 , Oct 21, 2008 |  BC Extra  |  Financial News

S*BIO raises $26 million

S*BIO (Singapore) raised US$26 million in a series B round co-led by existing investor Bio*One Capital and new investor Aravis Venture. New investors Lacuna Apo BioTech Fund, which is advised by Adamant Biomedical Investments, and...
07:00 , Aug 18, 2008 |  BC Week In Review  |  Company News

Serentis board of directors update

Serentis Ltd. , Cambridge, U.K.   Business: Dermatology, Other   Appointed: Bill Blair, CEO of Adamant Biomedical Investments Ltd.’s Adamant Ventures subsidiary  ...
07:00 , Jun 2, 2008 |  BioCentury  |  Finance

Ebb & Flow

Southern exposure...
07:00 , Apr 21, 2008 |  BioCentury  |  Finance

Ebb & Flow

Less than a month after completing its acquisition of cancer and infectious disease company Celldex in a stock deal for about $75 million,...
07:00 , Apr 7, 2008 |  BioCentury  |  Finance

2Q Financial Markets Preview: Longing for normalcy

With stock market volatility expected to continue this quarter, investors say they will continue the flight to quality that began at the end of last year. The few buysiders who are not sitting on the...
08:00 , Jan 21, 2008 |  BioCentury  |  Regulation

System reset in 2008

Years of negative publicity over adverse effects of drugs and unrelenting political pressure to minimize risks have reshaped the American regulatory environment, effectively creating new requirements for approval that sponsors and investors ignore at their...
07:00 , Aug 13, 2007 |  BioCentury  |  Finance

Ebb & Flow

A pair of high-profile setbacks among two of Germany's late-stage biotech companies has left the country's biotech industry with only a handful of Phase III products. Thus, investors are starting to view the German landscape...
07:00 , Apr 30, 2007 |  BioCentury  |  Finance

Ebb & Flow

Two U.S. IPOs debuted last week, the first since early February. Both offered Phase III stories, but timing was about all they otherwise had in common. Outcomes for the two - obesity play...
08:00 , Feb 26, 2007 |  BioCentury  |  Finance

Ebb & Flow Focus

Actelion Ltd. (SWX:ATLN) shed $615 million in market value last week, despite reporting that 2006 EPS jumped 85%, as investors apparently have some concerns about what’s ahead for the company. Revenues and EPS have been...
07:00 , Jun 26, 2006 |  BioCentury  |  Finance

What Actelion's investors want

Disappointing preliminary data from Actelion Ltd. 's Phase III CONSCIOUS-1 trial of clazosentan might re-open a debate on whether the European bellwether needs to fill its mid- to late-stage pipeline gap through in-licensing or M&A....